Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HAE
Haemonetics Corporation (HAE) EV/Sales
As of 16 October 2026, Haemonetics Corporation (HAE) trades at a EV/Sales of 4.7×. Over the past ten years it has ranged from 1.7× (May 2016) to 8.1× (February 2021); the current reading is higher than 76% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 2.7× | (2.80%) |
| FY2025 | 2.8× | (25.42%) |
| FY2024 | 3.8× | (6.02%) |
| FY2023 | 4.0× | 12.57% |
| FY2022 | 3.6× | (49.53%) |
| FY2021 | 7.0× | 33.25% |
| FY2020 | 5.3× | 6.94% |
| FY2019 | 4.9× | 21.10% |
| FY2018 | 4.1× | 63.92% |
| FY2017 | 2.5× | 11.36% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.2× | 18.08% |
| Mar 2026 | 2.7× | (16.64%) |
| Dec 2025 | 3.3× | 47.39% |
| Sep 2025 | 2.2× | (29.25%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LIVN LivaNova PLC compare | 2.7× |
| BRKR Bruker Corporation compare | 2.9× |
| ITGR Integer Holdings Corporation compare | 3.0× |
| PODD Insulet Corporation compare | 3.3× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.6× |
| IRTC iRhythm Holdings, Inc. compare | 4.4× |
| HAE Haemonetics Corporation | 4.7× |
| GKOS Glaukos Corporation compare | 15.9× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)